CURRICULUM VITAE - Pancreatic Cancer India

Dr. SV Shrikhande’ CV
Methylnaltrexone Bromide ((MNTX) in the treatment of postoperative
ileus (POI)
430 Risk factors for colorectal cancer in India: INDOX Case-control study CI
450 A phase II study to evaluate the role of conformal hepatic radiation in CI
unresectable hepatocellular carcinoma and hepatic metastases
466 Identification of post translational modifications / variants of histones
for exploitation as biomarker in patients with gastric cancer
Principal
Investigator
487 The risk of hepatocellular carcinoma in patients with chronic liver CI
disease of viral etiology and iron deficiency
512 A multicenter, Randomized, Double-Blind, phase 3 study of CI
Sunitinib in Metastatic colorectal
cancer patients receiving irinotecan, 5 Fluorouracil and Leucovorin
(FOLFIRI) as first line treatment
565 Randomized, phase III-b, multi-centre, open-label, parallel study of
Enoxaparin (low molecular weight heparin) given concomitantly with
chemotherapy in patients with inoperable gastric and gastrooesophageal
cancer
571 A multinational , randomized, double blind, placebo-controlled, study
comparing the efficacy of Aflibercept once every 2 weeks versus
placebo in patients treated with Gemcitabine for metastatic
pancreatic cancer.
Principal
Investigator
CI
574 A randomized, double blind phase III study of Gemcitabine plus AG-
013736 versus Gemcitabine plus placebo for the first line treatment
of patients with locally advanced, unresectable or metastatic
pancreatic cancer
591 A Randomized double blind multicentre phase II/ III study to
compare the efficacy of cediranib ( RECENTIN TM , AZD2171)
incombination with 5-fluorouracil, leucovorin, and Oxaliplatin
(FOLFOX), to the efficacy of bevacizumab in combination with
FOLFOX in patients with previouslyuntreated metastic colorectal
cancer
759 A dose tolerability and efficacy study of RX-0201 plus gemcitabine in
metastatic pancreatic cancer
Principal
Investigator
Principal
Investigator
Principal
Investigator
48